Jasmiel®

(drospirenone and ethinyl estradiol tablets, USP) 3 mg/0.02 mg

Jasmiel® is an AB-rated generic oral contraceptive.

Compares to

Yaz®, Gianvi™, Loryna®, Lo-Zumandimine™, and Nikki™

NDC#

50102-240-23

View Full Prescribing Information, Including Boxed Warning
Jasmiel Product Packaging Jasmiel Product Packaging with Pills In Front Jasmiel Product Packaging Pill Pack Jasmiel Product Packaging Pouch
Jasmiel Product Packaging
Jasmiel Product Packaging with Pills In Front
Jasmiel Product Packaging Pill Pack
Jasmiel Product Packaging Pouch

Product Details

  • A progestin/estrogen combination oral contraceptive
  • Monophasic 24/4 administration regimen
    • 24 light pink to pink tablets, each containing 3 mg drospirenone USP (DRSP) and 0.02 mg ethinyl estradiol USP (EE)
    • 4 green placebo tablets to help ease administration
    • Combined in a 28-day tablet blister pack

Product Sheet

The Product Information Sheet features a summary of all relevant product information including Jasmiel® (drospirenone and ethinyl estradiol tablets, USP) 3 mg/0.02 mg product details, product description, NDC number, and product features.

Download Now

Product Features:

  • Jasmiel is also FDA-approved to treat moderate acne for women and girls who are at least 14 years old only if the patient desires an oral contraceptive for birth control
  • Jasmiel can also help treat symptoms of premenstrual dysphoric disorder (PMDD) for women who choose to take an oral contraceptive for contraception

The most frequent adverse reactions in contraception and acne clinical trials were headache/migraine, menstrual irregularities, nausea/vomiting, breast pain/tenderness, and mood changes.

Drospirenone USP (DRSP)-containing combination oral contraceptives (COCs) may be associated with a higher risk of venous thromboembolism (VTE) than COCs containing the progestin levonorgestrel or some other progestins. Before initiating use of Jasmiel in a new COC user or a woman who is switching from a contraceptive that does not contain DRSP, consider the risks and benefits of a DRSP-containing COC in light of her risk of a VTE. Known risk factors for VTE include smoking, obesity, and family history of VTE, in addition to other factors that contraindicate use of COCs.

Distributor & Ordering Info

Jasmiel®

NDC#: 50102-240-23

Package Size: A Carton Containing 3 Pouches

Distributor Phone URL Order Number
ANDA 1-800-331-2632 (Ext. 74591) www.andanet.com 329302
ASD Healthcare 1-800-746-6273 www.asdhealthcare.com 54018
Cardinal Health 1-800-326-6457 www.cardinalhealth.com 5515960
McKesson 1-855-625-6285 www.mckesson.com 3564416
McKesson Medical-Surgical 1-855-571-2100 mms.mckesson.com 1233219
Morris & Dickson 1-888-376-7409 www.morrisdickson.com 584797
R & S Northeast 1-800-262-7770 www.rsnortheast.com 024023

Order Jasmiel®
(drospirenone and ethinyl estradiol tablets, USP)

Order Now

Contact Your
Afaxys Pharma
Account Manager

Contact Now

View All
Afaxys Pharma
Products

View Now
Need help? Contact an Afaxys Account Manager